JPWO2023278860A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023278860A5 JPWO2023278860A5 JP2023580922A JP2023580922A JPWO2023278860A5 JP WO2023278860 A5 JPWO2023278860 A5 JP WO2023278860A5 JP 2023580922 A JP2023580922 A JP 2023580922A JP 2023580922 A JP2023580922 A JP 2023580922A JP WO2023278860 A5 JPWO2023278860 A5 JP WO2023278860A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- administered
- cancer
- trilaciclib
- sacituzumab govitecan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163217716P | 2021-07-01 | 2021-07-01 | |
| US63/217,716 | 2021-07-01 | ||
| PCT/US2022/035995 WO2023278860A1 (en) | 2021-07-01 | 2022-07-01 | Combination treatments in patients with advanced and/or metastatic trop-2 overexpressed cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024524461A JP2024524461A (ja) | 2024-07-05 |
| JPWO2023278860A5 true JPWO2023278860A5 (https=) | 2025-07-09 |
| JP2024524461A5 JP2024524461A5 (https=) | 2025-07-09 |
Family
ID=84692161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023580922A Pending JP2024524461A (ja) | 2021-07-01 | 2022-07-01 | 進行性および／または転移性ｔｒｏｐ－２過剰発現ガンを有する治療困難患者における併用治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240139196A1 (https=) |
| EP (1) | EP4362948A4 (https=) |
| JP (1) | JP2024524461A (https=) |
| KR (1) | KR20240029045A (https=) |
| CN (1) | CN118215481A (https=) |
| AU (1) | AU2022301309A1 (https=) |
| CA (1) | CA3223467A1 (https=) |
| IL (1) | IL309489A (https=) |
| TW (1) | TW202317131A (https=) |
| WO (1) | WO2023278860A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL303038B2 (en) | 2016-12-05 | 2024-08-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| TWI842274B (zh) * | 2022-12-15 | 2024-05-11 | 中化合成生技股份有限公司 | 曲拉西利之製備方法及曲拉西利之前驅體 |
| CN120624660A (zh) * | 2024-08-06 | 2025-09-12 | 中山大学附属第三医院 | Fn1抑制剂在制备诊断、预防和治疗结直肠癌骨髓转移的产品中的用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202112061RA (en) * | 2019-05-15 | 2021-11-29 | Ayala Pharmaceuticals Inc | Bisfluoroalkyl-1,4-benzodiazepin one compounds for treating notch-activated breast cancer |
| EP3986410A4 (en) * | 2019-06-18 | 2023-06-28 | G1 Therapeutics, Inc. | Patient selection for enhancement of anti-tumor immunity in cancer patients |
-
2022
- 2022-07-01 CN CN202280057773.6A patent/CN118215481A/zh active Pending
- 2022-07-01 EP EP22834324.0A patent/EP4362948A4/en active Pending
- 2022-07-01 TW TW111124849A patent/TW202317131A/zh unknown
- 2022-07-01 AU AU2022301309A patent/AU2022301309A1/en active Pending
- 2022-07-01 CA CA3223467A patent/CA3223467A1/en active Pending
- 2022-07-01 IL IL309489A patent/IL309489A/en unknown
- 2022-07-01 WO PCT/US2022/035995 patent/WO2023278860A1/en not_active Ceased
- 2022-07-01 KR KR1020247003327A patent/KR20240029045A/ko active Pending
- 2022-07-01 JP JP2023580922A patent/JP2024524461A/ja active Pending
-
2023
- 2023-12-22 US US18/394,512 patent/US20240139196A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514787A5 (https=) | ||
| JP2011503111A5 (ja) | ４−ヨード−３−ニトロベンズアミド化合物と抗腫瘍剤の組み合わせによる乳がんの治療 | |
| JP2017516802A5 (https=) | ||
| JP2010043114A (ja) | 腫瘍転移および癌の治療 | |
| JP2010043115A (ja) | 腫瘍転移および癌の治療における５−フルオロウラシルの有効性の増強 | |
| JP2019038796A5 (https=) | ||
| WO2017118401A1 (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
| Bokemeyer et al. | A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer | |
| JP2019038797A5 (https=) | ||
| Legha et al. | Phase I study of spirogermanium given daily. | |
| Markman | Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity | |
| KR101978108B1 (ko) | 암 세포의 대사 특이성에 기초하는 신규 항 악성 종양제 | |
| JPWO2023278860A5 (https=) | ||
| US20130101680A1 (en) | Radiotherapy enhancer | |
| JPWO2019196764A5 (https=) | ||
| JP2006528696A (ja) | 抗癌剤の抗腫瘍活性を増強する方法 | |
| EP3654967A1 (en) | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer | |
| CN114173785B (zh) | 用于治疗非小细胞肺癌的氨基吡啶衍生物 | |
| JP2013531064A (ja) | 難治性癌を治療する方法 | |
| Lee et al. | Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma | |
| JPWO2019161054A5 (https=) | ||
| Yamaguchi et al. | Combination chemotherapy with 5-fluorouracil, cisplatin and paclitaxel for pretreated patients with advanced gastric cancer | |
| JPWO2023078881A5 (https=) | ||
| Davidov | Oxaliplatin/5-fluorouracil/leucovorin in the treatment of patients with metastatic colorectal cancer | |
| Fu et al. | Efficacy and side effects of combined capecitabine plus intensity modulated radiotherapy as an effective adjuvant therapy for gastric cancers |